Fostamatinib

Contraindicated

Fostamatinib Colchicine Colcrys Increased colchicine exposure and an increased risk of colchicine toxicity Details Fostamatinib Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details

Major

Fostamatinib Abametapir Increased exposure of CYP3A4 substrate Details Fostamatinib Relugolix Orgovyx Increased relugolix exposure Details Fostamatinib Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Fostamatinib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Fostamatinib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Fostamatinib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Fostamatinib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Fostamatinib Digoxin Cardoxin® Increased digoxin exposure Details Fostamatinib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Fostamatinib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Fostamatinib Alfentanil Increased ALfentanil exposure and an increased risk of respiratory depression Details Fostamatinib Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Fostamatinib Artemether Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Fostamatinib Atazanavir Reyataz Increased fostamatinib active metabolite (R406) exposure and an increased risk of fostamatinib-related adverse effects (eg., hepat... Details Fostamatinib Avacopan Tavneos Increased CYP3A4 substrate exposure Details Fostamatinib Carbamazepine Carbatrol Reduced exposure to the active metabolite Details Fostamatinib Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Fostamatinib Conivaptan Vaprisol Increased CYP3A substrate exposure Details Fostamatinib Cyclosporine Atopica Increased cycloSPORINE exposure Details Fostamatinib Doxorubicin Hydrochloride Liposome Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Fostamatinib Ensartinib Increased ensartinib exposure Details Fostamatinib Enzalutamide Xtandi Reduced exposure to the active metabolite Details Fostamatinib Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Fostamatinib Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Fostamatinib Fexinidazole An increased CYP3A4 substrate exposure Details Fostamatinib Fosphenytoin Cerebyx Reduced exposure to the active metabolite Details Fostamatinib Haloperidol Increased haloperidol exposure and an increased risk of haloperidol-related adverse events, including QTc interval prolongation Details Fostamatinib Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Fostamatinib Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Fostamatinib Lemborexant Dayvigo Increased lemborexant exposure and an increased risk of lemborexant-related adverse reactions. Details Fostamatinib Letermovir Prevymis Increased CYP3A substrate exposure Details Fostamatinib Lomitapide Increased lomitapide exposure Details Fostamatinib Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Fostamatinib Lumacaftor Reduced exposure to the active metabolite Details Fostamatinib Mavorixafor Xolremdi Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Fostamatinib Methylergonovine Methergine Increased methylergonovine exposure Details Fostamatinib Mifepristone Korlym Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Fostamatinib Mitotane Lysodren Reduced exposure to the active metabolite Details